Elon Musk's company Neuralink will begin the first clinical trials of its revolutionary brain implant technology in October, Bloomberg reports.
The first tests will take place in the US and will be aimed at helping people with severe speech impairments. The goal of the project is to enable communication to be restored to those who have lost the ability to speak.
According to the company, the implant should read signals directly from the brain and transform them into speech. If the tests are successful, Neuralink plans to bring the technology to the broad market by 2030.
The US Food and Drug Administration (FDA) has already granted permission for these tests.
It was previously reported that by 2031, the company aims to implant about 20,000 neurochips annually and open five specialized clinics in the US. Three main areas of use for the implants are envisaged: restoring vision, treating neurodegenerative diseases, and controlling a computer with the power of thought.
